TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting

04 Apr 2022 06:44:26 By Nasdaq GlobeNewswire

TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting

10 Mar 2022 07:15:30 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting

04 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL

03 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results

01 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

25 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update

24 Feb 2022 06:30:01 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference

24 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

05 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting

14 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

14 Dec 2021 06:15:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting

13 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting

10 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Provides Regulatory Update

30 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the Jefferies London Healthcare Conference

15 Nov 2021 06:30:01 By Nasdaq GlobeNewswire

TG Therapeutics Highlights Data Selected for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

04 Nov 2021 08:34:14 By Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

04 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business Update

01 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

14 Oct 2021 09:45:00 By Nasdaq GlobeNewswire